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Impact of oral meloxicam administered alone or in combination with
gabapentin on experimentally induced lameness in beef calves
Abstract
This study examined the pharmacokinetics and analgesic effect of oral meloxicam (MEL) administered alone
or in combination with gabapentin (GABA) in an experimental bovine lameness model. Eighteen male
British × Continental beef calves aged 4 to 6 mo and weighing 297 to 392 kg were randomly assigned to
receive either 1) 0.5 mg/kg lactose monohydrate placebo (PLBO; n = 6), 2) 0.5 mg/kg MEL (n = 6), or 3)
0.5 mg/kg MEL combined with 15 mg/kg GABA (MEL-GABA; n = 6) once daily for 4 d. The first treatment
was administered 4 h after a chemical synovitis/arthritis was induced with injection of 15 mg amphotericin B
into the left hind lateral distal interphalangeal joint. Changes in activity were evaluated continuously with
pedometers. Contact force, contact area, contact pressure, impulse, and stride length were recorded once daily
with a pressure mat and visual lameness scores were determined by a masked observer using a 5-point scale.
Cortisol and drug concentrations were determined daily by immunoassay and HPLC-mass spectrometry,
respectively. Outcomes were compared statistically using a random effects mixed model and analysis of
covariance. There was a positive association between lameness scores and serum cortisol concentrations (P =
0.02) and a negative association between lameness score and step count (P < 0.0001), total force (P = 0.001),
force applied to the lateral claw (P= 0.02), contact pressure (P = 0.005), and impulse of the lateral claw (P =
0.01). Step count was greater in MEL calves compared with PLBO (P = 0.008) and MEL-GABA (P = 0.04)
calves. Impulse was greater in the MEL-GABA calves compared with the PLBO calves (P = 0.03). There was
an inverse relationship between plasma MEL concentrations and lameness score (P = 0.02) and a positive
association between MEL concentrations and force applied to the lateral claw (P = 0.03), total contact
pressure (P = 0.03), and impulse on the lateral claw (P = 0.02). There was a tendency towards a positive
association between GABA concentrations, total impulse, and impulse on the lateral claw (P = 0.08) and a
negative associate between GABA concentrations and step count (P = 0.08). The results of this study suggest
that MEL administered alone or in combination with GABA reduced the severity of lameness in calves
following induction of lameness with amphotericin B. These findings have implications for developing
analgesic protocols in lame calves that address both production and welfare concerns.
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INTRODUCTION
Involuntary culling of lame cattle has a significant 
impact on both dairy and beef production. The preva-
lence of lameness in dairy herds has been reported as 
33.7 and 36.8% in Wisconsin and the United Kingdom, 
respectively (Cook, 2003; Barker et al., 2010). Roeber 
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ABSTRACT: This study examined the pharmacoki-
netics and analgesic effect of oral meloxicam (MEL) 
administered alone or in combination with gabapentin 
(GABA) in an experimental bovine lameness model. 
Eighteen male British × Continental beef calves aged 
4 to 6 mo and weighing 297 to 392 kg were randomly 
assigned to receive either 1) 0.5 mg/kg lactose monohy-
drate placebo (PLBO; n = 6), 2) 0.5 mg/kg MEL (n = 6), 
or 3) 0.5 mg/kg MEL combined with 15 mg/kg GABA 
(MEL-GABA; n = 6) once daily for 4 d. The first treat-
ment was administered 4 h after a chemical synovitis/
arthritis was induced with injection of 15 mg ampho-
tericin B into the left hind lateral distal interphalangeal 
joint. Changes in activity were evaluated continuously 
with pedometers. Contact force, contact area, contact 
pressure, impulse, and stride length were recorded 
once daily with a pressure mat and visual lameness 
scores were determined by a masked observer using 
a 5-point scale. Cortisol and drug concentrations were 
determined daily by immunoassay and HPLC-mass 
spectrometry, respectively. Outcomes were compared 
statistically using a random effects mixed model and 
analysis of covariance. There was a positive association 
between lameness scores and serum cortisol concen-
trations (P = 0.02) and a negative association between 
lameness score and step count (P < 0.0001), total force 
(P = 0.001), force applied to the lateral claw (P = 0.02), 
contact pressure (P = 0.005), and impulse of the lateral 
claw (P = 0.01). Step count was greater in MEL calves 
compared with PLBO (P = 0.008) and MEL-GABA (P 
= 0.04) calves. Impulse was greater in the MEL-GABA 
calves compared with the PLBO calves (P = 0.03). 
There was an inverse relationship between plasma 
MEL concentrations and lameness score (P = 0.02) and 
a positive association between MEL concentrations and 
force applied to the lateral claw (P = 0.03), total contact 
pressure (P = 0.03), and impulse on the lateral claw (P 
= 0.02). There was a tendency towards a positive asso-
ciation between GABA concentrations, total impulse, 
and impulse on the lateral claw (P = 0.08) and a nega-
tive associate between GABA concentrations and step 
count (P = 0.08). The results of this study suggest that 
MEL administered alone or in combination with GABA 
reduced the severity of lameness in calves following 
induction of lameness with amphotericin B. These 
findings have implications for developing analgesic 
protocols in lame calves that address both production 
and welfare concerns.
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et al. (2001) found that 31.4% of cattle audited in the 
1999 National Market Cow and Bull Beef Quality Audit 
were lame. Tibbetts et al. (2006) reported a 6.5% preva-
lence of foot rot in feedlot steers and observed that lame 
calves spent an average of 5 d longer on feed and gained 
0.049 kg/d less during the finishing period than nonaf-
fected cattle. As a consequence, the direct cost of lame-
ness in the feedyard is estimated to be US$59.94/case. 
Lameness is one of the most important welfare 
challenges in livestock production and is considered a 
chronic pain syndrome because hyperalgesia persists 
for at least 28 d after the causal lesion has resolved (Ley 
et al., 1996; Whay et al., 1998, 2003). Lameness pain 
has both an inflammatory and neuropathic component. 
Inflammatory pain responds modestly to treatment 
with nonsteroidal anti-inflammatory drugs (NSAID; 
Whay et al., 2005; Flower et al., 2008) but neuropathic 
pain is considered refractory to the effects of NSAID 
(Woolf and Mannion, 1999). Gabapentin (GABA) is a 
γ-aminobutyric acid analogue used extensively for the 
management of chronic pain in humans (Hurley et al., 
2002; Cheng and Chiou, 2006). Meloxicam (MEL) is a 
NSAID that is approved outside the United States as an 
adjunctive therapy of acute respiratory disease, diarrhea, 
and acute mastitis. The pharmacokinetic profile of oral 
GABA and MEL supports clinical evaluation of these 
compounds for management of chronic pain in cattle 
(Coetzee et al., 2011). The present study was conducted 
to test the hypothesis that oral MEL administered alone 
or in combination with GABA would mitigate signs of 
experimentally induced lameness in beef calves. 
MATERIALS AND METHODS
All experimental procedures in this study were ap-
proved by the Kansas State University (KSU) Institution-
al Animal Care and Use Committee under the supervision 
of the University Veterinarian (protocol number 2863).
Experimental Cattle
Eighteen male British × Continental beef calves aged 
4 to 6 mo and weighing 297 to 392 kg were acquired 
from a Kansas livestock producer. On arrival calves re-
ceived florfenicol (Nuflor; Merck Animal Health, Sum-
mit, NJ; lot number 8668101) for control of bovine re-
spiratory disease at 40 mg/kg, doramectin pour-on (Dec-
tomax; Pfizer Animal Health, Madison, NJ; lot number 
OAWM7) as an anthelmintic at 500 μg/kg, permethrin 
pour-on (Ultraboss; Merck Animal Health; lot number 
90414C) for fly control at 1 mL/15 kg, and a clostridial 
vaccine (Covexin 8; Merck Animal Health; lot number 
1381C). All animals were examined on arrival and were 
found to be healthy and subjectively free from lameness 
with the exception of 4 animals that presented with signs 
of bovine keratoconjunctivitis. These cattle responded to 
therapy with florfenicol before study commencement. 
Housing and Husbandry
Study calves were initially housed in a dry lot con-
finement facility at KSU Animal Resource Facility for 
approximately 90 d after arrival. Thereafter, calves were 
blocked by body weight and randomly assigned to 3 pens 
of 6 calves each, so that each pen contained 2 calves 
from each treatment group. Pens comprised a linear row 
of outdoor concrete pads (9.75 by 18.29 m), each with 
a partial roof over straw bedding. The diet consisted of 
water and grass hay ad libitum with a ration composed 
of cracked corn, alfalfa pellets, soybean meal, molasses, 
vitamins, and minerals delivered at 5 to 6 kg per calf per 
day, divided and offered twice daily in open bunks. Due 
to the nature of the diet and the housing arrangement, it 
was not possible to measure individual feed intake. 
Jugular Catheterization
Approximately 24 h before study commencement, 
all calves were individually restrained in a squeeze 
chute using a rope halter and the attached head gate. Fol-
lowing restraint, the area over the right jugular vein in 
period 1 and the left jugular vein in period 2 was clipped 
and disinfected using povidone iodine and 70% isopro-
pyl alcohol swabs. The catheter site was infiltrated with 
approximately 0.5 mL of 2% lidocaine injection (Hospi-
ra Inc., Lake Forest, IL) and a small skin incision with a 
number 22 blade was made to facilitate placement of a 
14 gauge (G) by 140 mm catheter (Abbocath-T; Abbott 
Ireland, Sligo, Rep. of Ireland), which was sutured to the 
skin using 2–0 nylon suture (Burns Veterinary Supply, 
Inc., Westbury, NY). Catheter patency was maintained 
by twice daily flushing using 3 mL heparin saline con-
taining 3 IU heparin sodium/mL 0.9% saline (Heparin 
Sodium Injection, USP; Baxter Healthcare Corporation, 
Deerfield, IL). The catheters were removed immediately 
after the last blood collection time point in each period.
Group Assignment, Randomization, and  
Study Procedures
The study was conducted using a parallel design with 
a period of baseline data collection (period 1) followed 
by a study period (period 2). Before period 1, study ani-
mals were blocked by body weights determined 24 h 
before study commencement and randomly assigned to 
treatment groups based using a computer-generated ran-
dom number (Microsoft Excel 2007; Microsoft Corpora-
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tion, Redmond, WA) to ensure that treatment groups had 
similar mean body weights (Fig. 1).
Baseline Data Collection (Period 1)
The study commenced at 17 h 25 min on d –7 with 
an acclimatization period, which included collection 
of baseline data (cortisol, pedometer, and pressure mat 
data) from nonarthritic calves (period 1) collected once 
daily for 5 d. Baseline data were used as a covariate to 
improve the fit of the statistical model that was used to 
compare treatment effects following lameness induction. 
Lameness Induction (Period 2)
Period 2 commenced on d 0 with lameness induction. 
Before lameness induction, all calves were restrained in 
a chute with head gate as conducted throughout the ac-
climatization period, and the left hind leg was restrained 
with ropes at the fetlock and stifle. After restraint, the 
lateral digit pastern region was prepared with close clip-
ping of hair (number 40 clipper blade) and aseptic skin 
preparation using povidone iodine scrub and 70% iso-
propyl alcohol swabs. Lameness was induced as previ-
ously described (Kotschwar et al., 2009; Schulz et al., 
2011). Briefly, a sterile 18 G 1 1/2-inch (3.8-cm) needle 
was inserted 1 cm proximal to the coronary band and 
1 cm abaxial to the tendon of the long digital extensor 
muscle and angling distally toward the sole. After the 
sterile needle was inserted, correct placement into the 
distal interphalangeal joint was verified by aspiration of 
synovial fluid back into the syringe. A dose of 15 mg 
amphotericin B (X-Gen Pharmaceuticals, Inc., Big Flats, 
NY) was injected using 3 mL of a 5 mg/mL solution. 
Continued position within the distal interphalangeal 
joint was verified periodically throughout the injection 
by ease of injection followed by back-flow of synovial 
fluid and amphotericin B into the syringe. This solution 
was fully injected into the distal interphalangeal joint to 
complete the procedure. All procedures occurred at ap-
proximately 5 min intervals and were performed by a 
single veterinarian (DEA) to avoid interoperator varia-
tion.
Rescue analgesic therapy options for unresolved 
lameness after final data collection included flunixin 
meglumine at 2.2 mg/kg intravenously (IV) once daily, 
butorphanol tartrate at 0.05 mg/kg subcutaneously (SC) 
once daily, morphine at 0.1 mg/kg SC once daily, and 100 
mg of lidocaine 2% administered as a single intra-articular 
injection.
Drug Administration
At 4 h after lameness induction, 0.5 mg/kg MEL 
(Meloxicam tablets 15 mg [NDC 65862-098-01]; 
Aurobindo Pharma USA, Dayton, NJ; lot number 
MX1509019-A) was administered alone or in combina-
tion with 15 mg/kg GABA (Gabapentin capsules, USP 
100 mg and 400 mg [NDC 0228-2667]; Actavis Eliza-
beth LLC, Parsippany, NJ; lot number 832J91). The oral 
dose was rounded to the nearest whole capsule or tablet. 
Calves in the placebo (PLBO)-treated group received 
an equivalent dose of D (+)-lactose monohydrate (Fluka 
Analytical, Buchs, Germany), a pharmacologically inac-
tive excipient used in the manufacture of MEL tablets, 
by mouth (PO). Treatments were administered at 24 h 
(±1 h) intervals for 4 d. The contents of the capsules, 
whole tablets, and lactose powder was suspended in 50 
mL of water in a 60 mL catheter-tip syringe (BD Luer-
Lok Syringe; Becton-Dickinson, Franklin Lakes, NJ) 
and administered as an oral drench within 5 min of sus-
pension.
Blood Sample Collection
Fifteen milliliters of whole blood for determining 
drug concentrations in treated calves was collected into 
syringes using the preplaced jugular catheter immedi-
ately before lameness induction and again at 12, 24, 48, 
72, 84, 96, 108, 120, 132, and 144 h thereafter. Samples 
for assessing cortisol concentrations in all calves were 
collected into syringes using the preplaced jugular cath-
eter immediately before lameness induction and again 
at 12, 24, 48, 72, and 96 h thereafter. Immediately after 
obtaining the blood sample, 3 mL of heparin saline flush, 
as described above, was used to maintain patency of the 
catheter. Blood was immediately transferred to a 7 mL 
sodium heparin vacutainer tube (BD Diagnostics, Frank-
lin Lakes, NJ) and 7 mL vacutainer tube (BD Diagnos-
tics) containing no additive. The vacutainer tubes were 
stored on ice for no more than 60 min pending sample 
Figure 1. Flow chart outlining the timeline of study events after a 7 d 
acclimatization period, lameness induction with 15 mg of amphotericin B, and 
oral treatment with a placebo (PLBO) or meloxicam (MEL) at 0.5 mg/kg alone 
or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d.
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processing. Thereafter, blood samples were centrifuged 
at 1,600 × g for 15 min at 0°C. Serum and plasma were 
pipetted from their respective tubes and placed in cryo-
vials identified with calf identification, date, time point 
sample, and treatment group. The samples were stored 
at –80°C before sample analysis. All samples were ana-
lyzed within 60 d of sample collection. 
Plasma Gabapentin and Meloxicam Analysis
Plasma concentrations of GABA and MEL were de-
termined with HPLC (Shimadzu Prominence; Shimadzu 
Scientific Instruments, Columbia, MD) and mass spec-
trometry (API 2000; Applied Biosystems, Foster City, 
CA) as previously described (Coetzee et al., 2011; Mal-
reddy et al., 2013). Plasma samples or standards (100 μL) 
were added to 100 μL of internal standard (pregabalin 5 
μg/mL in methanol) and 400 μL of methanol with 0.1% 
formic acid to precipitate the proteins. Quantitation was 
performed by calculating the ratios of GABA m/z 172.1 
→ 154.1 and MEL m/z 352.09 → 114.90 responses rela-
tive to the internal standard m/z 160.00 → 142.00 transi-
tion. The samples were vortexed for 5 s and centrifuged 
for 10 min at 15,000 × g at 4°C. The supernatant, 200 
μL, was transferred to an injection vial with an injection 
volume of 25 μL. The mobile phase consisted of 100% 
B from 0 to 1 min with a linear gradient to 50% A and 
50% B at 3 min, which was maintained until 6 min, fol-
lowed by a linear gradient to 100% B at 6.5 min with a 
total run time of 8 min. The solvent “A” was acetonitrile 
and the solvent “B” was 0.1% formic acid at a flow rate 
of 0.4 mL/min. Separation was achieved with a phenyl 
column (Hypersil Gold, 150x2.1, 5 µM; Thermo Scien-
tific, Waltham, MA) maintained at 40°C. The standard 
curve was linear from 0.05 to 10 μg/mL for GABA and 
0.025 to 2.5 μg/mL for MEL and was accepted if the cor-
relation coefficient exceeded 0.99 and predicted values 
were within 15% of the actual values. The accuracy of 
the GABA assay was 97 ± 10% and the coefficient of 
variation was 10% determined on replicates of 3 at 0.05, 
0.1, 0.5, 5, and 10 µg/mL. The accuracy of the MEL as-
say was 100 ± 9% and the coefficient of variation was 
6% determined on replicates of 3 at 0.025, 0.05, 0.25, 
1.0, and 2.5 µg/mL. The limits of detection were 0.05 and 
0.025 μg/mL for GABA and MEL, respectively, defined 
as the lowest concentration on the standard curve with 
predicted concentrations within 15% of the actual con-
centration.
Pharmacokinetic Analysis
Pharmacokinetic analyses were performed with com-
puter software (WinNonlin 5.2; Pharsight Corporation, 
Cary, NC). The calculated variables included the area 
under the curve from time 0 to infinity using the linear 
trapezoidal rule and the terminal drug elimination half-
life. The accumulation index was calculated as the ratio 
between the peak plasma drug concentration (Cmax) at 
steady state and the Cmax after the first dose. The maxi-
mum (Cmax), minimum, and average plasma concentra-
tion and time to maximum serum concentration (Tmax) 
were determined directly from the data.
Clinical Lameness Scoring
The degree of lameness was scored using a 0 to 4 
scale adapted from Sprecher at al. (1997; Table 1) as 
previously described (Kotschwar et al., 2009). Lameness 
scores were determined once daily, after blood sample 
collection, to document presence of lameness and to vi-
sually score severity of lameness. To eliminate interob-
server variation, all lameness scores were assigned by 
1 blinded veterinarian (DEA) with training and exper-
tise in bovine lameness assessment. Intra-observer vari-
ability was assessed periodically by randomly selecting 
calves for repeated assessment to ensure consistency of 
scoring. All lameness examinations were performed on 
even, nonsloped concrete floors free of obstructions and 
debris. Each lameness score was determined by watch-
ing the calf walk a minimum of 20 m in a straight line, 
turn, and walk 20 m back to the starting point.
Cortisol Analysis
Serum cortisol concentrations were determined as 
previously described and validated in bovine plasma 
(Coetzee et al., 2007) using a solid-phase competitive 
chemiluminescent enzyme immunoassay and an auto-
mated analyzer system (Immulite 1000 Cortisol; Sie-
mens Medical Solutions Diagnostics, Los Angeles, CA). 
A sample volume of 100 μL was used in each assay well. 
The reported calibration range for the assay is 28 to 1,380 
nmol/L with an analytical sensitivity of 5.5 nmol/L.
Table 1. Sprecher lameness scoring system
Lameness  
  score Clinical description
0 Normal: stands and walks normally, with all feet placed with 
purpose
1 Mildly lame: stands with flat back but arches when walks and 
gait is slightly abnormal
2 Moderately lame: stands and walks with an arched back and 
short strides with 1 or more legs
3 Lame: arched back standing and walking, with 1 or more limbs 
favored but at least partially weight bearing
4 Severely lame: arched back, refuses to bear weight on 1 limb, or 
may refuse or have great difficulty moving from lying position
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Pedometer
Pedometers (NL-800; New-Lifestyles Inc., Lees 
Summit, MO) were placed within a protective neoprene 
sleeve that was attached to the lateral aspect of the meta-
tarsus immediately proximal to the fetlock as previously 
described (Hanzlicek et al., 2010). Pedometers con-
tained an accelerometer inside of them that monitored 
the number of steps each calf took based on the up and 
down movement of the calf leg. The pedometer data 
were recorded during the acclimatization period and for 
96 h after lameness induction at which time data were 
downloaded into a spreadsheet for analysis. 
Pressure Mat Analysis
A commercially available floor mat-based pressure/
force measurement system (MatScan; Tekscan, Inc., 
South Boston, MA) was used to record and analyze 
the affected feet of each calf as previously described 
(Kotschwar et al., 2009; Schulz et al., 2011). Data were 
collected once daily at the time of blood sample collec-
tion. The pressure mat was calibrated daily and each 
time the computer software was engaged using a known 
mass to ensure accuracy of the measurements at each 
time point. Video synchronization was used to ensure 
consistent gait between and within calves for each time 
point. Using research grade software (HUGEMAT Re-
search 5.83; Tekscan, Inc.), contact pressure, contact 
area, impulse, and stance phase duration in the affected 
feet were measured. Surface area was calculated by area 
only of the loaded or “contact” sensing elements inside 
the measurement box. Contact pressure was calculated 
as force on the loaded sensing elements inside the mea-
surement box divided by the contact area. Impulse was 
calculated as the area under the force vs. time curve. 
This reflects the association between force and the time 
the foot was on the ground. The stance phase duration 
was determined as the period of time when the foot was 
in contact with the ground. 
Average Daily Weight Gain
Calves were individually weighed on d 0 and 4 us-
ing a commercial livestock scale (For-Most Livestock 
Equipment, Hawarden, IA). Food and water were not 
withheld before weighing. Average daily gain was cal-
culated by subtracting the prelameness weight and the 
postlameness weight and dividing this by the number of 
days that passed between weigh dates.
Data Analysis and Statistics
Hypothesis tests were conducted using the GLIM-
MIX procedure of SAS (version 9.2; SAS Inst. Inc., 
Cary, NC). The mean ± SEM were calculated for each 
outcome variable at each time point. Mean baseline 
outcome values were used as covariates in regression 
models. Two structures of fixed effects were considered. 
One is ANOVA structure with treatment group, time, 
and their interaction; the other is an analysis of cova-
riance type with drug concentrations (MEL or GABA; 
continuous), lameness score, and time (categorical) in-
cluded in the model. Model assumptions were consid-
ered to be appropriately met based on diagnostics con-
ducted on studentized residuals. Estimated least square 
means and corresponding standard errors are presented. 
A significant difference was considered to exist when P 
≤ 0.05, and a marginal difference was considered to exist 
if 0.05 < P ≤ 0.10. Relevant pairwise comparisons were 
conducted when the significance of the interaction term 
was P ≤ 0.10 using Tukey-Kramer or Bonferroni adjust-
ments, as appropriate in each case, to avoid inflation of 
Type I error rate due to multiple comparisons. Analy-
sis of variance was also used to evaluate differences in 
single measurement, normally distributed data (ADG).
RESULTS AND DISCUSSION
Meloxicam and Gabapentin Plasma Concentrations 
Following oral administration, plasma MEL concen-
trations declined slowly over the course of the study (Ta-
ble 2; Fig. 2 and 3). In contrast, GABA was more rapidly 
eliminated from the plasma resulting in a shorter elimi-
nation half-life compared with MEL (Table 2; Fig. 3). 
There was no difference in plasma MEL concentrations 
in calves that received MEL alone compared with calves 
that received MEL combined with GABA (P > 0.5). 
Meloxicam is an NSAID of the oxicam class that 
is approved in the European Union and Canada for ad-
junctive therapy of acute respiratory disease, diarrhea, 
and acute mastitis and the alleviation of pain associat-
ed with disbudding in calves when administered at 0.5 
mg/kg IV or SC (European Agency for the Evaluation 
of Medicinal Products [EMEA], 1999). Gabapentin is 
a γ-aminobutyric acid analogue originally developed 
for the treatment of spastic disorders and epilepsy in 
humans (Cheng and Chiou, 2006). Studies have estab-
lished that GABA is also effective for the management 
of chronic pain of inflammatory or neuropathic origin 
(Hurley et al., 2002). Although the mechanism of action 
of GABA is poorly understood, it is thought to bind to 
the α2-δ subunit of voltage gated calcium channels act-
ing presynaptically to reduce the release of excitatory 
neurotransmitters (Taylor, 2009). The justification for 
co-administering GABA with MEL in the present study 
was the reported synergistic interaction with NSAID to 
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produce antihyperalgesic effects (Hurley et al., 2002; 
Picazo et al., 2006).
In a recent study we reported that the mean (±SD) 
Cmax, Tmax, and half-life for GABA (15 mg/kg) co-
administered as a single oral dose with MEL (1 mg/kg) 
was 3.57 ± 1.04 μg/mL, 7.33 ± 1.63 h, and 8.12 ± 2.11 
h, respectively (Coetzee et al., 2011). The mean (±SD) 
Cmax, Tmax, and half-life for MEL in the same study 
was 2.11 ± 0.19 μg/mL, 11.67 ± 3.44 h, and 20.47 ± 9.22 
h, respectively. These concentrations are comparable to 
the steady state plasma concentrations maintained for 
the duration of the present study following once daily 
administration for 4 d. 
The pharmacokinetic–pharmacodynamic relation-
ship and dose response to MEL in horses with induced 
carpal arthritis has been previously reported (Toutain 
and Cester, 2004). Based on this work, the reported half 
maximal effective concentration (EC50) for MEL in 
the plasma of lame horses is approximately 0.2 μg/mL. 
Plasma GABA concentrations >2 μg/mL in humans are 
associated with a lower frequency of seizures (Sivenius 
et al., 1991). Similar doses are used to treat epilepsy and 
neuropathic pain suggesting that these concentrations 
will also be effective for analgesia. Concentrations above 
these levels were maintained for both drugs throughout 
the present study indicating that this treatment regimen 
was appropriate to achieve the goals of the trial. 
In the United States, use of MEL and GABA for al-
leviating pain associated with lameness constitutes ex-
tra-label drug use (ELDU; Coetzee et al., 2009; Smith 
and Modric, 2013). Under the Animal Medicinal Drug 
Use Clarification Act of 1994 (U.S. Food and Drug Ad-
ministration, 1994), ELDU is permitted for relief of 
suffering in cattle provided specific conditions are met. 
These conditions include that 1) ELDU is permitted only 
by or under the supervision of a veterinarian, 2) ELDU 
is allowed only for Food and Drug Administration ap-
proved animal and human drugs, (3) ELDU is only per-
mitted when the health of the animal is threatened and 
not production purposes, (4) ELDU in feed is prohibited, 
and (5) ELDU is not permitted if it results in a viola-
tive food residue. Therefore, use of MEL and GABA to 
Table 2. Mean (± SD) meloxicam and gabapentin plasma pharmacokinetic parameters following lameness induction 
with amphoterecin B and treatment with oral meloxicam (MEL) at 0.5 mg/kg once daily alone or in combination with 
oral gabapentin (MEL-GABA) at 15 mg/kg once daily for 4 d. The maximum (Cmax), minimum (Cmin), and average 
(Cavg) plasma concentration and time to maximum serum concentration (Tmax) were determined directly from the 
data. The calculated variables included the area under the curve from time 0 to infinity (AUC INF) using the linear 
trapezoidal rule and the terminal drug elimination half-life (HL_Lambda_z). The accumulation index was calculated 
as the ratio between the Cmax at steady state and the Cmax after the first dose. 
Treatment 
  group Outcome HL_Lambda_z, h Tmax, h Cmax, μg/mL Cmin, μg/mL Cavg, μg/mL
AUC INF, h × 
μg/mL
Accumulation 
index
MEL MEL mean 22.49 89.60 4.70 3.21 4.08 276.78 1.95
MEL SD 8.81 6.57 1.47 1.31 1.17 93.84 0.51
MEL-GABA MEL mean 23.37 87.65 4.44 2.76 3.67 219.85 1.99
MEL SD 6.96 6.20 1.13 1.04 1.14 71.87 0.40
MEL-GABA GABA mean 9.45 84.00 3.97 1.81 2.94 94.70 1.21
GABA SD 0.63 0.00 1.49 1.08 1.22 42.85 0.03
Figure 3. Mean ± SE for plasma meloxicam (MEL) and gabapentin 
(GABA) concentrations after oral treatment with 0.5 mg/kg MEL alone or 
in combination with 15 mg/kg GABA once daily for 4 d (arrows) following 
lameness induction with amphotericin B at 6 h before first treatment. 
Figure 2. Mean ± SE for plasma meloxicam (MEL) concentrations after 
oral treatment with 0.5 mg/kg MEL once daily for 4 d (arrows) following 
lameness induction with amphotericin B at 6 h before first treatment. 
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alleviate pain associated with lameness in cattle in the 
United States must by law comply with these regula-
tions (Coetzee, 2013a). At the conclusion of the present 
study all study animals were humanely euthanized and 
incinerated because a tissue withhold period for GABA 
in cattle has not been established. It is acknowledged 
that further research to establish a meat withhold period 
for GABA is needed before widespread use in animals 
intended for human consumption can be recommended. 
Clinical Lameness Scoring
There was evidence of a time effect on clinical lame-
ness score (P < 0.0001) but only marginal evidence of a 
treatment effect (P = 0.089) and no evidence of a time × 
treatment interaction (P = 0.76; Table 3; Fig. 4). Lame-
ness scores were higher at 24 (P = 0.005) and 48 h (P = 
0.02) after lameness induction across treatment groups. 
Lameness score tended to be greater in PLBO calves 
compared with MEL calves (P = 0.07) throughout the 
study but this was especially evident at 72 h after treat-
ment (P = 0.02). The relative distribution of lameness 
scores over time in each treatment group are presented 
in Fig. 5a, 5b, and 5c. At 96 h after lameness induction, 
100% of clinical lameness had resolved in the MEL 
group compared with 83% in the 0.5 mg/kg MEL com-
bined with 15 mg/kg GABA (MEL-GABA) group and 
only 50% in the PLBO group. Plasma MEL concentra-
tions were found to be inversely proportional to lame-
ness scores (P = 0.03; Table 4). No animals required 
rescue analgesia during the course of the study. 
Intra-articular injection of amphotericin B in the 
distal interphalangeal joint causes a chemical synovitis-
arthritis resulting in a transient lameness in cattle, pigs, 
and horses (Fahmy et al., 1994; Kotschwar et al., 2009; 
Schulz et al., 2011; Karriker et al., 2013). Amphotericin 
B is a polyene antimicrobial that is approved for use as 
an antifungal agent. Following intra-articular injection, 
amphotericin B causes an aseptic synovitis as a result 
of disrupting lysosomes and release of inflammatory 
mediators within the synovial tissue. The results of the 
present study confirm the appropriateness of this model 
for demonstrating analgesic drug efficacy because lame-
ness was reliably induced in all animals for at least 96 h 
after injection of amphotericin B. 
The analgesic efficacy of IV administered flunixin 
meglumine (1 mg/kg) has been previously evaluated us-
ing an amphotericin B induced lameness model (Schulz 
et al., 2011). Compared to untreated controls, animals 
receiving flunixin meglumine at the time of lameness 
induction and 12 h later were less likely to be lame as 
determined by clinical lameness score. In contrast, sodi-
um salicylate (50 mg/kg) administered IV failed to sig-
nificantly mitigate clinical signs following amphotericin 
B induced lameness in 4- to 6-mo-old steers (Kotschwar 
et al., 2009). The results of the present study provide 
evidence that MEL mitigated clinical lameness, thus 
providing support for our hypothesis.
Although the clinical response to treatment with MEL 
alone was similar to MEL-GABA in the present study, 
it should be noted that there were no calves with lame-
ness scores of 3 or 4 at the time treatment was initiated. 
Given that more severe lameness scores are commonly 
Table 3. Mean (±SE) outcome measures after lameness 
induction with amphoterecin B and treatment with oral 
meloxicam (MEL) at 0.5 mg/kg once daily alone or in 
combination with oral gabapentin (MEL-GABA at 15 
mg/kg PO) once daily for 4 d
Parameter
LS1 means (±SE) P-values
PLBO2 MEL
MEL-
GABA Treatment Time
Treatment 
× time
Sprecher 
lameness  
score, 0–4
1.33
(0.29)
0.38
(0.29)
0.79
(0.29)
0.09 <0.0001 0.76
Cortisol, 
nmol/L
15.78
(1.19)
15.18
(1.18)
15.79
(1.18)
0.98 <0.0001 0.25
Step count 3,224.03a
(163.70)
4,086.59b
(176.98)
3,424.63a
(161.36)
0.01 <0.0001 0.92
Total force,  
kg force
788.75
(36.48)
863.81
(36.25)
910.20
(36.87)
0.10 0.30 0.59
Force (lateral 
claw), kg 
force
495.93
(47.38)
621.29
(47.86)
637.64
(48.28)
0.10 0.45 0.31
Force  
(medial 
claw), kg 
force
394.94
(23.04)
336.94
(23.09)
313.61
(24.25)
0.07 0.21 0.89
Total contact 
area, cm2
50.81
(1.59)
49.30
(1.57)
51.08
(1.60)
0.70 0.38 0.37
Contact area 
(lateral 
claw), cm2
28.96
(1.34)
30.25
(1.35)
31.67
(1.36)
0.38 0.20 0.13
Contact area 
(medial  
claw), cm2
24.29
(1.10)
21.39
(1.07)
21.18
(1.12)
0.12 0.52 0.98
Total contact 
pressure,  
kg/cm2
15.88
(0.90)
17.40
(0.90)
17.90
(0.91)
0.28 0.30 0.93
Total impulse, 
kg × s
384.33a
(24.98)
409.77ab
(27.11)
488.43b
(26.81)
0.03 0.12 0.80
Impulse  
(lateral 
claw), kg × s
235.06
(25.41)
282.97
(26.27)
320.73
(26.30)
0.09 0.33 0.68
Impulse 
(medial 
claw), kg × s
152.02
(17.76)
145.86
(19.00)
152.53
(19.16)
0.97 0.38 0.37
Stance phase 
duration, s
0.75
(0.03)
0.78
(0.04)
0.82
(0.03)
0.36 0.59 0.48
Stride length, 
cm
62.47
(1.46)
66.64
(1.42)
65.68
(1.43)
0.15 0.55 0.41
a,bDifferent superscripts indicate significant differences between treatments.
1LS = least square.
2PLBO = placebo.
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recorded at the start of analgesic therapy in field cases of 
lameness, an effect of GABA in cattle with established 
central sensitization cannot be excluded based on these 
results. However, these findings support the conclusion 
that administration of MEL alone at 0.5 mg/kg once daily 
would alleviate pain associated with early cases of mild 
(score 1 or 2) lameness. Further research is needed to as-
sess the efficacy of MEL and GABA in alleviating pain 
in cattle with more severe, naturally acquired lameness.
Serum Cortisol Concentrations
There was a positive association between log-trans-
formed serum cortisol concentrations and increasing 
clinical lameness scores (P = 0.02) but there was no 
evidence of a treatment effect or time × treatment inter-
action on serum cortisol concentrations (Table 3). Nev-
ertheless, there was evidence of a time effect on circulat-
ing cortisol concentrations (Fig. 6). Specifically, serum 
cortisol concentrations were elevated at 12 h after lame-
ness induction in all treatment groups (P < 0.0001) but 
there was no difference in cortisol concentrations noted 
at any other time points. There was also no evidence of 
an association between log-transformed serum cortisol 
concentrations and circulating MEL (P = 0.13) or GABA 
(P = 0.54) concentrations (Table 4). 
Cortisol secretion is a critical component of the 
physiologic stress response. Although plasma cortisol 
measurements have been the most extensively used as-
sessment tool of pain-induced stress in models of acute 
pain in cattle such as dehorning and castration, the rela-
tionship between stress and plasma cortisol concentra-
tion is not always clear (Coetzee., 2013b). Confound-
ing factors such as handling-induced distress must be 
differentiated from pain-induced stress (Coetzee et al., 
2008). In the present study, plasma cortisol concentra-
tions significantly differed over the study period. This 
is consistent with the findings reported in previous stud-
ies that induced lameness with amphotericin B to assess 
the efficacy of analgesic compounds (Kotschwar et al., 
2009; Schulz et al., 2011).
Figure 5. Distribution of lameness scores after oral treatment with a lac-
tose monohydrate placebo (PLBO; n = 6; panel a), 0.5 mg/kg of meloxicam 
(MEL; n = 6; panel b), or 0.5 mg/kg of MEL combined with 15 mg/kg gaba-
pentin (MEL-GABA; n = 6; panel c) once daily for 4 d following lameness 
induction with amphotericin B at 6 h before first treatment. Lameness scores 
(LS)  were assigned according to the following system; LS0 = normal: stands 
and walks normally, with all feet placed with purpose; LS 1 = mildly lame: 
stands with flat back but arches when walks; gait is slightly abnormal; LS 2 = 
moderately lame: stands and walks with an arched back and short strides with 
1 or more legs; LS 3 = lame: arched back standing and walking, with 1 or 
more limbs favored but at least partially weight bearing; and LS 4 = severely 
lame: arched back, refuses to bear weight on 1 limb, or may refuse or have 
great difficulty moving from lying position
Figure 4. Mean ± SE lameness scores after oral treatment with a placebo 
(PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/
kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction 
with amphotericin B at 6 h before first treatment. a,bTime points not connected 
by the same letter are significantly different (P < 0.05. Lameness Score (LS); 
0 = normal: stands and walks normally, with all feet placed with purpose; LS 
1 = mildly lame: stands with flat back but arches when walks; gait is slightly 
abnormal; LS 2 = moderately lame: stands and walks with an arched back and 
short strides with 1 or more legs; LS 3 = lame: arched back standing and walk-
ing, with 1 or more limbs favored but at least partially weight bearing; and LS 
4 = severely lame: arched back, refuses to bear weight on 1 limb, or may refuse 
or have great difficulty moving from lying position
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Kotschwar et al. (2009) reported that mean serum 
cortisol concentration was less in calves with a lameness 
score of 1 compared to that of calves with a lameness 
score of 3 (P = 0.004) after lameness induction with am-
photericin B. It was also reported that cortisol concen-
trations tended to be elevated in control calves following 
lameness induction with amphotericin B compared with 
calves treated with 1 mg/kg flunixin meglumine (Schulz 
et al., 2011). Taken together these results combined with 
the findings of the present study support the assertion 
that pain associated with induced lameness causes ac-
tivation of the hypothalamic–pituitary axis resulting in 
elevated serum cortisol concentrations. 
Recently it was reported that plasma cortisol con-
centrations and lameness scores were significantly re-
duced in cows that received 0.5 mg/kg MEL IV once 
daily for 4 d following resection of the distal interpha-
langeal joint (Offinger et al., 2013). This finding contra-
dicts the results of the present study that found no as-
sociation between MEL administration and a reduction 
in cortisol concentrations in calves after induction of 
lameness. One explanation for these equivocal findings 
is that plasma cortisol concentrations were elevated for 
several days following digital resection compared with 
an increase only at 24 h after experimental lameness 
induction in the present study. This may have increased 
the likelihood of an analgesic drug mitigating serum 
cortisol concentration after digital resection because 
the overall magnitude and duration of the response was 
greater than in the present study. 
Step Count
Step count was inversely proportional to clinical lame-
ness score (P < 0.0001; Table 5). An effect of treatment (P 
= 0.01) and time (P < 0.0001) on the number of steps taken 
after lameness induction was recorded using pedometers 
but no time × treatment interaction was observed (P = 0.92; 
Fig. 7; Table 3). Specifically, calves in the MEL group 
took more steps after lameness induction than calves in 
the PLBO group (P = 0.008) and the MEL-GABA group 
(P = 0.04). However, there was no difference in step count 
between the PLBO group and the MEL-GABA group (P 
= 0.67). There was also a positive association between in-
creasing plasma MEL concentrations and the number of 
steps taken after lameness induction (P = 0.0002) but step 
count tended to be inversely proportional to plasma GABA 
concentrations (P = 0.08; Table 4). 
Table 4. Intercept, slope, and SEM for the correlation 
between plasma drug concentrations and the outcome 
measures after lameness induction with amphoterecin B 
and treatment with oral meloxicam (MEL) at 0.5 mg/kg 
once daily alone or in combination with oral gabapentin 
(GABA; 15 mg/kg PO) once daily for 4 d
Parameter
Intercept
(±SEM)
Regression slope 
estimate (±SEM) P-values
MEL GABA MEL GABA
S precher lameness 
score, 0–4
7.37
(2.30)
–0.13
(0.06)
0.19
(0.12)
0.03 0.12
L og cortisol, nmol/L 1.75
(0.79)
–0.07
(0.04)
0.06
(0.09)
0.13 0.54
Step count 1,669.36
(599.44)
189.73
(46.70)
–160.61
(88.88)
0.0002 0.08
T otal force,  
kg force
1,066.53
(188.46)
23.20
(12.43)
24.30
(21.85)
0.07 0.27
F orce (lateral  
claw), kg force
468.08
(180.47)
27.09
(11.98)
19.88
(21.90)
0.03 0.37
F orce (medial claw), 
kg force
289.34
(65.96)
–11.62
(7.11)
–10.62
(13.61)
0.11 0.44
T otal contact  
area, cm2
37.61
(9.74)
–0.61
(0.51)
0.42
(0.87)
0.24 0.63
C ontact area (lateral 
claw), cm2
28.02
(7.89)
0.35
(0.44)
0.41
(0.81)
0.43 0.62
C ontact area (medial 
claw), cm2
15.27
(3.48)
–0.45
(0.33)
–0.43
(0.62)
0.18 0.49
T otal contact 
pressure, kg/cm2
3.90
(5.31)
0.55
(0.25)
0.67
(0.48)
0.03 0.17
T otal impulse,  
kg × s
404.55
(79.50)
9.49
(9.43)
31.38
(17.70)
0.32 0.08
I mpulse (lateral 
claw), kg × s
214.71
(48.95)
15.27
(6.42)
21.45
(11.60)
0.02 0.07
I mpulse (medial 
claw), kg × s
110.23
(33.57)
–1.43
(5.56)
–4.14
(11.08)
0.80 0.71
S tance phase 
duration, s
0.49
(0.11)
0.01
(0.01)
0.02
(0.02)
0.41 0.41
Stride length, cm 46.49
(16.18)
0.57
0.44
0.55
0.87
0.20 0.53
Figure 6. Mean ± SE serum cortisol concentrations after oral treatment 
with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination 
with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness 
induction with amphotericin B at 6 h before first treatment. a,bTime points not 
connected by the same letter are significantly different (P < 0.05). Lameness 
Score (LS); 0 = normal: stands and walks normally, with all feet placed with 
purpose; LS 1 = mildly lame: stands with flat back but arches when walks; gait 
is slightly abnormal; LS 2 = moderately lame: stands and walks with an arched 
back and short strides with 1 or more legs; LS 3 = lame: arched back standing 
and walking, with 1 or more limbs favored but at least partially weight bearing; 
and LS 4 = severely lame: arched back, refuses to bear weight on 1 limb, or 
may refuse or have great difficulty moving from lying position
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A reduction in the number of steps in lame cattle 
compared with sound cattle has been recorded using 
pedometers attached to a sound rear limb (O’Callaghan 
et al., 2003). This indicates that cattle tend to reduce 
their activity to avoid weight loading to the painful limb 
(Shearer et al., 2013). It was previously reported that 
calves treated with 1 mg/kg flunixin at the time of lame-
ness induction with amphotericin B were more active 
than untreated controls (Schulz et al., 2011). In a recent 
study it was reported that cows that received 0.5 mg/
kg MEL IV once daily for 4 d following resection of 
the distal interphalangeal joint took more steps per hour 
than control cattle (Offinger et al., 2013). The results of 
the present study support this observation. However, the 
reduction in the number of steps taken in the MEL-GA-
BA-treated calves compared with the calves that were 
treated with MEL alone was unexpected. The tendency 
for step count to be inversely proportional with circulat-
ing GABA concentrations suggests that this may have 
been directly associated with the effects of the drug. It 
is noteworthy that GABA administration in humans is 
associated with sedation and dizziness (Mao and Chen, 
2000). We therefore hypothesize that GABA may have 
a mildly sedative effect in cattle that could have contrib-
uted to the reduction in activity. To our knowledge, this 
is the first study to report a direct association between 
analgesic drug concentrations and changes in activity in 
lame cattle. These data may assist in the development of 
analgesic drug regimens in lame calves that address both 
production and welfare concerns.
Pressure Mat Analysis
Force. Clinical lameness score was inversely pro-
portional to total force (P = 0.001) and force applied to 
the lateral claw (P = 0.02; Table 5). However, there was 
no effect of treatment (P = 0.10) or time (P = 0.30) or 
evidence of a time × treatment interaction (P = 0.59) on 
the total force applied to the claw after lameness induc-
tion (Table 3). There was evidence of a weak positive as-
sociation between plasma MEL concentrations and the 
total force applied to the lame claw (P = 0.07; Table 4).
When each claw was examined individually, there 
was no effect of treatment (P = 0.10) or time (P = 0.45) 
on the force applied to the lateral claw. However, there 
was evidence of a positive association between increas-
ing plasma MEL concentrations and force applied to the 
lateral claw (P = 0.03; Table 4). There was also marginal 
evidence of an effect of treatment on the force applied 
to the medial claw after lameness induction (P = 0.07). 
Specifically, calves in the PLBO group tended to apply 
Table 5. Intercept, slope, and SE for the correlation 
between Sprecher lameness score and the outcome mea-
sures after lameness induction with amphoterecin B and 
treatment with oral meloxicam at 0.5 mg/kg once daily 
alone or in combination with oral gabapentin (15 mg/kg 
PO) once daily for 4 d
Parameter
Intercept 
(±SE)
Regression 
slope estimate 
(±SE) P-value
Log cortisol, nmol/L
1.26
(0.66)
0.20
(0.08)
0.02
Step count
2,468.92
(501.20)
–487.77
(84.81)
<0.0001
Total force, kg force
1,146.92
(157.34)
–84.92
(24.65)
0.001
Force (lateral claw), kg force
562.47
(170.17)
–65.81
(26.37)
0.02
Force (medial claw), kg force
240.77
(68.90)
23.16
(16.55)
0.17
Total contact area, cm2
38.75
(9.24)
–0.40
(1.13)
0.72
Contact area (lateral claw), cm2
28.14
(7.01)
–1.46
(0.90)
0.11
Contact area (medial claw), cm2
13.76
(3.51)
1.13
(0.71)
0.12
Total contact pressure, kg/cm2
8.90
(4.42)
–1.56
(0.53)
0.005
Total impulse, kg × s
381.27
(77.09)
–37.08
(25.74)
0.16
Impulse (lateral claw), kg × s
219.71
(48.86)
–51.21
(18.69)
0.01
Impulse (medial claw), kg × s
105.09
(26.56)
6.41
(11.60)
0.58
Stance phase duration, s
0.53
(0.10)
–0.0007
(0.03)
0.98
Stride length, cm
44.23
(16.92)
–0.43
(0.95)
0.65
Figure 7. Mean ± SE step count assessed with pedometer after oral 
treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or 
in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d 
following lameness induction with amphotericin B at 6 h before first treat-
ment. a,bTime points not connected by the same letter are significantly differ-
ent (P < 0.05). Lameness Score (LS); 0 = normal: stands and walks normally, 
with all feet placed with purpose; LS 1 = mildly lame: stands with flat back but 
arches when walks; gait is slightly abnormal; LS 2 = moderately lame: stands 
and walks with an arched back and short strides with 1 or more legs; LS 3 = 
lame: arched back standing and walking, with 1 or more limbs favored but at 
least partially weight bearing; and LS 4 = severely lame: arched back, refuses 
to bear weight on 1 limb, or may refuse or have great difficulty moving from 
lying position
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more force to the medial claw after lameness induction 
than calves in the MEL-GABA group (P = 0.07). 
When the force applied to the lateral claw was ex-
pressed as a percentage of the total force applied to the 
claw, a treatment effect was observed (P = 0.03) but 
there was no effect of time (P = 0.22) or time × treat-
ment interaction (P = 0.66; Fig. 8). Specifically, calves 
in the MEL group had a greater percentage of force dis-
tributed to the lateral claw than PLBO calves (P = 0.03). 
Calves in the MEL-GABA group also tended to have a 
greater force distribution to the lateral claw than calves 
in the PLBO group (P = 0.08). As expected, when the 
force applied to the medial claw was expressed as a per-
centage of the total force applied to the claw, a treatment 
effect was also observed (P = 0.04) but there was no ef-
fect of time (P = 0.75) or time × treatment interaction (P 
= 0.29; Fig. 9). Specifically, calves in the PLBO group 
tended to have a greater percentage of the total force 
distributed to the medial claw than calves in the MEL-
GABA group (P = 0.04).
In healthy cattle, force is primarily exerted on the 
lateral claw at the point of heal strike after which the 
load becomes shifted to the medial claw (van der Tol et 
al., 2002). Weight shifting occurs in lame cattle resulting 
in a reduction of vertical ground forces in affected limbs 
and redistribution of weight from the lateral to the medi-
al claw especially in the hind limbs (Schulz et al., 2011). 
Pressure mat analysis allows detection of subtle changes 
in weight distribution between claws that is useful in de-
tecting analgesic drug efficacy (Shearer et al., 2013). In 
the present study, induction of lameness manifested as 
a redistribution of force from the lateral to the medial 
claw. Administration of analgesia resulted in increas-
ing weight distribution to the lateral claw that was as-
sociated with increasing plasma MEL concentrations. 
This is similar to the findings reported by Schulz et al. 
(2011) that steers receiving flunixin meglumine applied 
a greater maximum and mean force on the affected limb 
during the stance phase compared with control steers. 
Taken together these findings support the hypothesis that 
MEL reduced the severity of lameness likely due to the 
analgesic and anti-inflammatory effects of the drug.
Contact Area. There was no relationship between 
clinical lameness score, total contact area, or the con-
tact area of the individual claws (Table 5). Furthermore, 
there was no effect of treatment or time or evidence of 
a time × treatment interaction on the total or individual 
contact area of the claw after lameness induction (Table 
3). There was also no association between plasma drug 
concentrations and the contact area (Table 4). 
The results reported herein conflict with the find-
ings reported by Kotschwar et al. (2009) and Schulz et al. 
(2011) that observed a significant decrease in contact area 
following lameness induction with amphotericin B. One 
explanation for this is that the lameness that was induced 
with 20 mg amphotericin B in the previous studies was 
more severe than the lameness induced with15 mg ampho-
tericin B in the present study. This would also explain why 
there was no treatment effect observed in the present study. 
Contact Pressure. Total pressure applied to the claw 
after lameness induction was inversely proportional to 
clinical lameness score (P = 0.005; Table 5). However, 
there was no effect of treatment (P = 0.28) or time (P = 
0.30) or evidence of a time × treatment interaction (P = 
0.93) on the contact pressure applied to the claw after 
lameness induction (Table 3). Nevertheless, there was a 
positive association between an increase in total contact 
Figure 9. Mean ± SE percent force distributed to the medial claw after 
oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone 
or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 
d following lameness induction with amphotericin B at 6 h before first treat-
ment. a,bTime points not connected by the same letter are significantly differ-
ent (P < 0.05).
Figure 8. Mean ± SE percent force distributed to the lateral claw after 
oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone 
or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 
d following lameness induction with amphotericin B at 6 h before first treat-
ment. a,bTime points not connected by the same letter are significantly differ-
ent (P < 0.05).
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pressure applied to the lame claw and plasma MEL con-
centrations (P = 0.03). 
These findings contradict those reported by 
Kotschwar et al. (2009) who reported that contact pres-
sure tended to be directly proportional to lameness score. 
This was likely because mean contact area decreased sig-
nificantly in the previous study resulting in force being 
distributed over a smaller area, thus increasing the total 
contact pressure. Furthermore, in that study there was no 
effect of treatment with intravenous sodium salicylate 
on contact pressure following lameness induction with 
amphotericin B. The positive association between MEL 
concentrations and contact pressure reported herein sug-
gests that analgesic drug administration maintained both 
the force applied to the affected limb and surface area on 
which this was applied. 
Impulse. Although there was no association between 
clinical lameness score and total impulse (P = 0.16) and 
impulse of the medial claw (P = 0.58), there was an in-
verse relationship between impulse on the lateral claw 
and clinical lameness score (P = 0.01; Table 5). There 
was also evidence of a treatment effect on total impulse 
(P = 0.03) but no effect of time (P = 0.12) or time × treat-
ment interaction (P = 0.80; Table 3). Specifically, total 
impulse was less in PLBO-treated calves compared with 
MEL-GABA-treated calves over the course of the study 
(P = 0.0286). Furthermore, there was marginal evidence 
of a treatment effect on impulse of the lateral claw (P 
= 0.09), which was also due to the tendency of PLBO-
treated calves to have a lower impulse than MEL-GA-
BA-treated calves (P = 0.077). There was also evidence 
of a weak positive association between plasma GABA 
concentrations and the total impulse (P = 0.08) and im-
pulse on the lateral claw (P = 0.07; Table 4). Increasing 
plasma MEL concentrations was also positively associ-
ated with an increase in impulse on the lateral claw (P 
= 0.02). It was previously reported that flunixin-treated 
steers tended to have a higher impulse on the affected 
limb during the stance phase than did control steers (P 
= 0.06; Schulz et al., 2011). The results of the present 
study provide further support for field investigations that 
test the hypothesis that MEL combined with GABA will 
reduce the severity of lameness especially in advanced 
cases where central sensitization has become established.
Stance Phase Duration and Stride Length. There 
was no association between lameness score and stance 
phase duration (P = 0.98; Table 5). Furthermore, there 
was no effect of treatment (P = 0.36), time (P = 0.59), 
or time × treatment interaction (P = 0.48) observed in 
the study (Table 3). Changes in drug concentrations 
were also not associated with changes in stance phase 
(Table 4). There was also no association between lame-
ness score and stride length (P = 0.65; Table 5). Further-
more, there was no effect of treatment (P = 0.15), time 
(P = 0.55), or time × treatment interaction (P = 0.41) ob-
served in the study (Table 3). Changes in drug concen-
trations were also not associated with changes in stride 
length (Table 4). These findings indicate that lameness 
induction and subsequent drug administration did not 
significantly impact these outcomes.
Average Daily Weight Gain
There was no significant difference in ADG between 
treatment groups over the course of the study (P = 0.15; 
Fig. 10). The difference in ADG between calves in the 
MEL-GABA group and calves in the PLBO group and 
MEL group was 2.30 ± 1.10 (P = 0.13) and 1.30 ± 1.10 
kg/d (P = 0.49), respectively. The numerical difference 
in ADG between the MEL-GABA group and the PLBO 
group was surprising because both groups were less ac-
tive than calves within the MEL group based on the pe-
dometer results. It was recently reported that calves treat-
ed with MEL-GABA had a greater ADG after dehorning 
compared to calves receiving either MEL (P = 0.02) or 
GABA (P = 0.0006) alone (Glynn et al., 2013). This find-
ing suggests the potential for a synergistic effect of these 
compounds for improving the growth and performance 
of calves after a painful event but further research is 
needed before widespread use can be recommended. It is 
noteworthy that pedometer measurements are not useful 
for assessing the time budgets and the relative location 
of calves within a pen. Therefore, the reduced activity of 
the calves does not necessarily imply that they spent less 
time at the feed bunk. The recent validation of remote 
triangulation devices to assess cattle time budgets and 
relative location within a pen could further elucidate the 
effect of analgesic compounds on cattle behavior after 
lameness induction (Theurer et al., 2012). 
The results of this study provide further support for 
the effectiveness of an intra-articular injection of am-
photericin B as being a useful model for studying lame-
ness in cattle. Oral MEL administered once daily for 
4 d had a positive effect on step count after lameness 
induction and increasing drug concentrations produced 
lower lameness scores and was positively associated 
with increased total contact pressure, force, and impulse 
applied to the lateral claw. The combination of GABA 
and MEL had a positive effect on the impulse applied to 
the lame claw but appeared to produce a mild sedative 
effect in treated cattle. Although the results of this study 
assist in the development of analgesic protocols in lame 
cattle that will address both production and welfare con-
cerns, further research in cattle with naturally acquired 
lameness is needed before widespread use of these com-
pounds can be recommended. 
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